Is aripiprazole (Abilify) effective for treating bipolar depression and bipolar hypomania?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Aripiprazole (Abilify) for Bipolar Depression and Hypomania

Aripiprazole is FDA-approved and effective for treating acute mania and preventing manic relapses in bipolar I disorder, but it is NOT established as effective for bipolar depression or hypomania. 1

Efficacy by Phase of Illness

For Acute Mania (NOT Hypomania)

Aripiprazole demonstrates clear efficacy for acute manic episodes in bipolar I disorder:

  • FDA-approved for acute mania in adults at doses of 15-30 mg/day 2
  • Effect size of 0.34 vs placebo at week 3, with response beginning as early as day 3 3
  • Number needed to treat (NNT) is 6 for response and 14 for remission 3
  • Most common adverse effects include akathisia (13%), sedation (8%), restlessness (6%), tremor (6%), and extrapyramidal symptoms (5%) 1

Critical distinction: Aripiprazole is approved for mania, not hypomania. Hypomania is a less severe mood elevation that typically does not require the same aggressive pharmacological intervention as full manic episodes.

For Bipolar Depression

The evidence for aripiprazole in bipolar depression is negative:

  • Two randomized controlled trials showed aripiprazole reduced depressive symptoms early in treatment but failed to separate from placebo at the primary endpoint of week 8 4
  • Meta-analysis revealed only a weak effect size of 0.17 for acute bipolar depression 3
  • The negative findings are attributed to excessively high study doses (15-30 mg), rapid titration, and high placebo response rates 4

Important caveat: Post-hoc analysis suggests aripiprazole may be more effective at lower doses (1-5 mg) in patients with severe depressive symptoms 4, 5. One retrospective study of low-dose aripiprazole (1-5 mg) in bipolar II and bipolar NOS depression showed significant improvement, with 79% of patients improving or very much improving 5. However, this remains off-label use without FDA approval.

For Maintenance/Prevention

Aripiprazole shows asymmetric efficacy in maintenance treatment:

  • Effective for preventing manic relapses: Median survival time for aripiprazole was not evaluable (very long) vs 118-203 days for placebo 3
  • NOT effective for preventing depressive relapses: Failed to reduce time to depressive relapse compared to placebo 4, 6, 7
  • This limitation likely reflects study design recruiting patients with index manic episodes rather than depressive episodes 4

Clinical Algorithm

For acute mania in bipolar I disorder:

  1. Start aripiprazole 15 mg/day (can increase to 30 mg/day if needed)
  2. Monitor for akathisia and extrapyramidal symptoms
  3. Expect response within 3-7 days

For bipolar depression:

  1. Do NOT use aripiprazole as monotherapy based on current evidence
  2. Consider olanzapine-fluoxetine combination, which IS FDA-approved for bipolar depression 2
  3. If attempting aripiprazole off-label, use very low doses (1-5 mg) and allow adequate time for response 5

For hypomania:

  1. Aripiprazole is not indicated for hypomania
  2. Consider traditional mood stabilizers (lithium, valproate) or other atypical antipsychotics approved for acute mania 2

Common Pitfalls

  • Dosing error: Using high doses (15-30 mg) for bipolar depression leads to poor tolerability and treatment failure. If attempting off-label use for depression, start at 1-2 mg 5
  • Phase confusion: Aripiprazole treats mania, not depression or hypomania. The evidence base is fundamentally different across mood phases
  • Maintenance expectations: While effective for preventing mania, aripiprazole will not prevent depressive relapses 4, 6
  • Akathisia management: This is the most common adverse effect (13% vs 4% placebo) and can be mistaken for worsening anxiety or agitation 1

References

2
Guideline

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

Related Questions

Can Abilify Maintena (aripiprazole) be used for bipolar II disorder?
Can Abilify (aripiprazole) be used to treat bipolar depression?
In a bipolar patient not taking any other medications who has previously tolerated aripiprazole (Abilify), should I start with 15 mg daily or begin with a lower dose and titrate?
What evidence supports using aripiprazole (Abilify) 4 mg for a bipolar patient?
Can I start Abilify (aripiprazole) at 2.5 mg for maintenance treatment of bipolar mania?
What is the appropriate management of sinus tachycardia?
Should sertraline 100 mg be tapered rather than stopped abruptly?
What imaging study should be obtained for a palpable bony growth over the xiphoid process?
In a patient with frequent premature ventricular complexes who is taking metoprolol 25 mg and has suspected vasospastic angina, should metoprolol be stopped and diltiazem initiated?
In renal tubular acidosis, is the anion gap elevated or normal?
What is the appropriate workup and management for a suspected thumb dislocation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.